Characterisation of the Pro-inflammatory Cytokine Signature in Severe COVID-19
Overview
Authors
Affiliations
Clinical outcomes from infection with SARS-CoV-2, the cause of the COVID-19 pandemic, are remarkably variable ranging from asymptomatic infection to severe pneumonia and death. One of the key drivers of this variability is differing trajectories in the immune response to SARS-CoV-2 infection. Many studies have noted markedly elevated cytokine levels in severe COVID-19, although results vary by cohort, cytokine studied and sensitivity of assay used. We assessed the immune response in acute COVID-19 by measuring 20 inflammatory markers in 118 unvaccinated patients with acute COVID-19 (median age: 70, IQR: 58-79 years; 48.3% female) recruited during the first year of the pandemic and 44 SARS-CoV-2 naïve healthy controls. Acute COVID-19 was associated with marked elevations in nearly all pro-inflammatory markers, whilst eleven markers (namely IL-1β, IL-2, IL-6, IL-10, IL-18, IL-23, IL-33, TNF-α, IP-10, G-CSF and YKL-40) were associated with disease severity. We observed significant correlations between nearly all markers elevated in those infected with SARS-CoV-2 consistent with widespread immune dysregulation. Principal component analysis highlighted a pro-inflammatory cytokine signature (with strongest contributions from IL-1β, IL-2, IL-6, IL-10, IL-33, G-CSF, TNF-α and IP-10) which was independently associated with severe COVID-19 (aOR: 1.40, 1.11-1.76, p=0.005), invasive mechanical ventilation (aOR: 1.61, 1.19-2.20, p=0.001) and mortality (aOR 1.57, 1.06-2.32, p = 0.02). Our findings demonstrate elevated cytokines and widespread immune dysregulation in severe COVID-19, adding further evidence for the role of a pro-inflammatory cytokine signature in severe and critical COVID-19.
Sanchez-Garcia S, Jaen R, Lozano-Rodriguez R, Avendano-Ortiz J, Pascual-Iglesias A, Hurtado-Navarro L Front Immunol. 2025; 15:1509188.
PMID: 39916956 PMC: 11798798. DOI: 10.3389/fimmu.2024.1509188.
Bartha-Tatar A, Sinkovits G, Schnur J, Maraczi V, David M, Zsigmond B J Clin Med. 2024; 13(23).
PMID: 39685637 PMC: 11642126. DOI: 10.3390/jcm13237177.
Paranga T, Mitu I, Pavel-Tanasa M, Rosu M, Miftode I, Constantinescu D Int J Mol Sci. 2024; 25(21).
PMID: 39518964 PMC: 11547016. DOI: 10.3390/ijms252111411.
Morrison L, Dyer A, Dolphin H, Batten I, Reddy C, Widdowson M Brain Behav Immun Health. 2024; 41:100862.
PMID: 39350951 PMC: 11440310. DOI: 10.1016/j.bbih.2024.100862.
Dyer A, Dolphin H, OConnor A, Morrison L, Sedgwick G, Young C Alzheimers Res Ther. 2024; 16(1):186.
PMID: 39160628 PMC: 11331802. DOI: 10.1186/s13195-024-01555-z.